CheckMate 743 Trial Update at 5 Years: New Insights on Mesothelioma Immunotherapy
The 5‑year follow‑up confirms that nivolumab plus ipilimumab provides sustained overall survival benefit in malignant pleural mesothelioma.
Long‑term survival benefit validates immunotherapy as first‑line option for pleural mesothelioma.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Moving Beyond Morphology: Toward a Morpho‑Molecular Classification of Pleural Mesothelioma
- Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System
- Systemic Treatments for Unresectable Pleural Mesothelioma: A Review of the Literature
- Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
- Tumor Treating Fields (TTFields) for Pleural Mesothelioma